Details for Patent: 11,166,960

Which drugs does patent 11,166,960 protect, and when does it expire?

Patent 11,166,960 protects OXTELLAR XR and is included in one NDA.

This patent has fourteen patent family members in ten countries.

Summary for Patent: 11,166,960

Title:	Modified release preparations containing oxcarbazepine and derivatives thereof
Abstract:	Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
Inventor(s):	Bhatt; Padmanabh P. (Rockville, MD), Kidane; Argaw (Montgomery Village, MD), Edwards; Kevin (Lovettsville, VA)
Assignee:	Supernus Pharmaceuticals, Inc. (Rockville, MD)
Application Number:	17/238,796
Patent Claim Types: see list of patent claims	Use; Formulation; Compound;

Drugs Protected by US Patent 11,166,960

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Supernus Pharms	OXTELLAR XR	oxcarbazepine	TABLET, EXTENDED RELEASE;ORAL	202810-001	Oct 19, 2012	AB	RX	Yes	No			Y
Supernus Pharms	OXTELLAR XR	oxcarbazepine	TABLET, EXTENDED RELEASE;ORAL	202810-002	Oct 19, 2012	AB	RX	Yes	No			Y
Supernus Pharms	OXTELLAR XR	oxcarbazepine	TABLET, EXTENDED RELEASE;ORAL	202810-003	Oct 19, 2012	AB	RX	Yes	Yes			Y

International Family Members for US Patent 11,166,960

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E496623
Australia	2007242984
Canada	2597740
China	101489560
Germany	602007012236
European Patent Office	2026815
European Patent Office	2359830